Akèy › Lekemi Selil Pwal
Etid klinik pou Lekemi Selil Pwal ap rekrite nan Etazini
10 etid pou Lekemi Selil Pwal ap rekrite patisipan nan sit atravè Etazini.
Vil ki gen plis etid
Pa eta
Etid ki fèk mete ajou
Tèks ofisyèl etid la (Anglè)
Collection of Human Samples to Study Hairy Cell and Other Leukemias, and to Develop Recombinant Immunotoxins for Cancer Treatment
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT01087333Binimetinib for People With Relapsed/Refractory BRAF Wild Type Hairy Cell Leukemia and Variant
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 16, 2026 · NCT04322383Phase I Study of Anti-CD22 Chimeric Receptor T Cells in Patients With Relapsed/Refractory Hairy Cell Leukemia and Variant
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 16, 2026 · NCT04815356A Study of Vemurafenib and Obinutuzumab Compared to Cladribine and Rituximab in People With Hairy Cell Leukemia (HCL)
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 9, 2026 · NCT06561360AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Aug 12, 2026 · NCT06340737Testing the Combination of Anti-cancer Drugs, Tovorafenib Plus Rituximab, in Patients With Hairy Cell Leukemia
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Jul 31, 2026 · NCT06965114Registry of Older Patients With Cancer
Ap rekriteEtid obsèvasyon
Laj 65 ak plis · Tout sèks · Mizajou Jun 29, 2026 · NCT01137825Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Jun 11, 2026 · NCT00412594Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies.
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Feb 13, 2026 · NCT04775745Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer
Ap rekriteEtid obsèvasyon
Laj 18 a 120 · Tout sèks · Mizajou Oct 27, 2025 · NCT01137643Sous ClinicalTrials.gov, done yo ranmase Oct 3, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.